# Pharmacokinetics of G3139 in Subjects With Advanced Melanoma, Including Those With Normal Hepatic Function and Those With Moderate Hepatic Impairment

> **NCT00543205** · PHASE2,PHASE3 · TERMINATED · sponsor: **Genta Incorporated** · enrollment: 6 (actual)

## Conditions studied

- Advanced Melanoma and Normal or Impaired
- Hepatic Function

## Interventions

- **DRUG:** Genasense® (G3139, oblimersen sodium)

## Key facts

- **NCT ID:** NCT00543205
- **Lead sponsor:** Genta Incorporated
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2005-08
- **Primary completion:** 2007-05
- **Final completion:** 2007-05
- **Target enrollment:** 6 (ACTUAL)
- **Why stopped:** Terminated due to very slow enrollment
- **Last updated:** 2011-11-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00543205

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00543205, "Pharmacokinetics of G3139 in Subjects With Advanced Melanoma, Including Those With Normal Hepatic Function and Those With Moderate Hepatic Impairment". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00543205. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*